BioCryst/$BCRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
- Ticker
- $BCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 435
- Headquarters
- Durham, United States
- Website
- www.biocryst.com
BioCryst Metrics
BasicAdvanced
$2.2B
-
-$1.68
0.56
-
Price and volume
Market cap
$2.2B
Beta
0.56
52-week high
$11.22
52-week low
$6.23
Average daily volume
5.1M
Financial strength
Current ratio
2.321
Quick ratio
2.219
Long term debt to equity
-1.739
Total debt to equity
-1.842
Interest coverage (TTM)
5.70%
Profitability
EBITDA (TTM)
433.047
Gross margin (TTM)
77.39%
Net profit margin (TTM)
-40.90%
Operating margin (TTM)
45.63%
Effective tax rate (TTM)
-0.91%
Revenue per employee (TTM)
$2,160,000
Management effectiveness
Return on assets (TTM)
52.86%
Return on equity (TTM)
87.84%
Valuation
Price to revenue (TTM)
2.067
Price to book
-4.76
Price to tangible book (TTM)
-4.76
Price to free cash flow (TTM)
5.206
Free cash flow yield (TTM)
19.21%
Free cash flow per share (TTM)
1.627
Growth
Revenue change (TTM)
68.72%
Earnings per share change (TTM)
840.75%
3-year revenue growth (CAGR)
45.30%
10-year revenue growth (CAGR)
43.62%
3-year earnings per share growth (CAGR)
9.03%
10-year earnings per share growth (CAGR)
5.52%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Analyst projections of the future price of BioCryst stock.
Bulls say / Bears say
ORLADEYO continues to grow: second-quarter sales were up 10% year on year excluding the divested European business, with management citing new patient demand and retention. The newly available oral pellet formulation also opens treatment to children aged 2 to under 12. (GlobeNewswire)
Navenibart offers a possible second HAE growth driver, and BioCryst completed enrolment in its pivotal Phase 3 trial. A European licensing deal brought $70 million upfront, with potential milestone payments and royalties if the programme advances commercially. (GlobeNewswire)
The business generated positive cash flow in the second quarter even excluding the navenibart licensing payment, and BioCryst had $354 million in cash and investments at quarter-end. It also cut its 2026 non-GAAP operating expense outlook to $420–440 million, which could support stronger ongoing profitability. (GlobeNewswire, GlobeNewswire)
A rival oral HAE preventive is advancing: Pharvaris reported an 83% reduction in monthly attacks in its Phase 3 study, prompting RBC to warn that it could curb ORLADEYO’s future growth. That threat is not yet a marketed product, but it could make it harder to add new patients. (Stocktwits)
The latest headline revenue increase overstates the strength of the core product trend: Q2 ORLADEYO revenue rose just 1% as reported, or 10% excluding Europe, while $55.7 million of navenibart licence revenue contributed to the quarter. BioCryst left its 2026 ORLADEYO sales outlook unchanged. (GlobeNewswire)
BioCryst’s balance sheet remains burdened by substantial financing claims: at June 30 it reported a $395.4 million secured term loan and $426.8 million in royalty financing obligations. Those obligations could limit flexibility if ORLADEYO sales weaken or new pipeline assets take longer to deliver. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioCryst News
AllArticlesVideos
Funds containing BioCryst
AllUSDEURGBP
Fund name | Fund size | $BCRX weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.20% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.20% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.20% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.14% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.